January - March 2010

March 25, 2010		Takeda Submits Application in Japan for Additional Indications of Alogliptin for Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide
March 19, 2010		Takeda Announces Withdrawal of Marketing Authorization Application for a Prolonged-Release Formulation of Competact® and discontinuation of its development in the EU
March 18, 2010		Takeda Launches Initiative for Capacity Development of Health Care Workers in Africa through programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria
March 16, 2010		A Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis Entered Into Phase 3 Clinical Programs in Japan
March 5, 2010		KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion
March 3, 2010		Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530
February 23, 2010		Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
February 18, 2010		HEMATIDE™ ENTERED INTO THE PHASE 3 CLINICAL PROGRAM TO TREAT ANEMIA IN CHRONIC RENAL FAILURE PATIENTS IN JAPAN
February 1, 2010		FIRST TREATMENT TO IMPROVE SURVIVAL IN 20 YEARS NOW AVAILABLE FOR PATIENTS WITH OSTEOSARCOMA (BONE CANCER)
January 18, 2010		Approval of Actos® Orally Disintegrating Tablets in Japan